Yüklüyor......
An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses
Oncolytic viruses offer an in situ vaccination approach to activate tumor-specific T cell responses. However, the upregulation of PD-L1 expression on tumor cells and immune cells leads to tumor resistance to oncolytic immunotherapy. In this study, we generate an engineered oncolytic virus that coexp...
Kaydedildi:
| Yayımlandı: | Nat Commun |
|---|---|
| Asıl Yazarlar: | , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Publishing Group UK
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7070065/ https://ncbi.nlm.nih.gov/pubmed/32170083 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-15229-5 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|